(Q44997646)

English

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

scientific article published on 17 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

13

object named as

Paul M Stewart

0 references

Alexandra Kautzky-Willer

object named as

Alexandra Kautzky-Willer

15

0 references

Andreas Pfeiffer

object named as

Andreas F Pfeiffer

14

0 references

Hans-Ulrich Häring

17

object named as

Hans-Ulrich Häring

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jürgen Harreiter

object named as

Jürgen Harreiter

10

0 references

Jürgen Machann

6

object named as

Jürgen Machann

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Konstantinos Kantartzis

5

object named as

Konstantinos Kantartzis

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

16

object named as

Michael Roden

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

8

object named as

Peter Nowotny

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Bettina Nowotny

4

object named as

Bettina Nowotny

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Markus Ramsauer

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Paul Jordan

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Jong-Hee Hwang

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sabine Kahl

9

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Silke Hornemann

11

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Arun J Sanyal

12

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sabine Fürst-Recktenwald

18

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

17 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

406-416

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Human fatty liver disease: old questions and new insights

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Abnormal hepatic energy homeostasis in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatty liver: a novel component of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of hepatokines in metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Does central obesity reflect "Cushing's disease of the omentum"?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The metabolically benign and malignant fatty liver

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970170-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(13)70170-0

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44997646&oldid=2147360612"